4577 Pharmaceuticals

GlaxoSmithKline plc Monitor

GlaxoSmithKline plc Annual Report 2016
CR Monitor Issue: 
2017/0811
Company covered: 
GlaxoSmithKline plc
Period End: 
31 December, 2016
Report issued on 22 August 2017 covered the following practice issues:
Restatement
Change in composition of reporting segments linked to restructuring of the business.
Change
Identification of new areas of audit focus in relation to "Acquisition-related liabilities" and "Finance transformation".
Pronouncements
Disclosure of proposed changes in non-audit services policy in line with Financial Reporting Council’s (FRC’s) revised Ethical Standards and new EU Audit Regulation.
Pronouncements
IFRIC interpretation leads to change in presentation in respect of cash pooling arrangements.
Restatement
Analysis of defined benefit scheme assets and obligations restated to exclude defined contribution plan amounts.

Novartis AG Monitor

Novartis AG Annual Report 2016
CR Monitor Issue: 
2017/0402
Company covered: 
Novartis AG
Period End: 
31 December, 2016
Report issued on 04 April 2017 covered the following practice issues:
Change
Change in segment disclosure to reflect changes in organisational structure.
Pronouncements
Introduction to audit report of a table disclosing key audit matters.
Change
Presentation of additional income statement, statement of changes in equity and cash flow statement comparative information.

AstraZeneca plc Monitor

AstraZeneca plc Annual Report 2015
CR Monitor Issue: 
2016/0911
Company covered: 
AstraZeneca plc
Period End: 
31 December, 2015
Report issued on 27 September 2016 covered the following practice issues:
Change
Redefinition of what is considered revenue with the reclassification of externalisation income from other operating income to revenue.

Roche Holding Ltd Monitor

Roche Holding Ltd Annual Report 2015
CR Monitor Issue: 
2016/0901
Company covered: 
Roche Holding Ltd
Period End: 
31 December, 2015
Report issued on 07 September 2016 covered the following practice issues:
Change
Finalisation of the accounting of business acquisition resulting in decrease to goodwill.
New
Recognition of restructuring costs including loss on divestment.

Deferred tax - Merck

Period End: 
31 December, 2015
Period End Date: 
2015-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
KPMG

Pensions - AstraZeneca plc

Period End: 
31 December, 2015
Period End Date: 
2015-12-31
Listing Status: 
FTSE 100, S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
KPMG

Pensions - Novartis AG

Period End: 
31 December, 2015
Period End Date: 
2015-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
PricewaterhouseCoopers

Pensions - Novartis AG

Period End: 
31 December, 2015
Period End Date: 
2015-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
PricewaterhouseCoopers

Share-based payments - Glaxosmithkline plc

Period End: 
31 December, 2014
Period End Date: 
2014-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
PricewaterhouseCoopers

Segmental information - Novartis AG

Period End: 
31 December, 2014
Period End Date: 
2014-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
PricewaterhouseCoopers